The Duke Human Vaccine Institute (DHVI) has established a place of national and international leadership in the fight against major infectious diseases. DHVI plays an integral leadership role in the Global HIV/AIDS Vaccine Enterprise and is a pioneer in emerging infections and biodefense research. By focusing on the scientific “bottlenecks” for the development of HIV, TB, and other vaccines, DHVI investigators continue to make significant contributions to overcome global health challenges on behalf of society. More

Press Releases

Human Immunodeficiency Virus

Recent Publications

Extensive Recombination Due to Heteroduplexes Generates Large Amounts of Artificial Gene Fragments during PCR.
Liu J, Song H, Liu D, Zuo T, Lu F, Zhuang H, Gao F. PLoS One. 2014 Sep 11;9(9):e106658. doi: 10.1371/journal.pone.0106658. eCollection 2014.

Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses.
Richard J, Veillette M, Batraville LA, Coutu M, Chapleau JP, Bonsignori M, Bernard N, Tremblay C, Roger M, Kaufmann DE, Finzi A. J Virol Methods. 2014 Aug 12;208C:107-114. doi: 10.1016/j.jviromet.2014.08.003. [Epub ahead of print]

Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies.
Kepler TB, Liao HX, Alam SM, Bhaskarabhatla R, Zhang R, Yandava C, Stewart S, Anasti K, Kelsoe G, Parks R, Lloyd KE, Stolarchuk C, Pritchett J, Solomon E, Friberg E, Morris L, Karim SS, Cohen MS, Walter E, Moody MA, Wu X, Altae-Tran HR, Georgiev IS, Kwong PD, Boyd SD, Fire AZ, Mascola JR,Haynes BF. Cell Host Microbe. 2014 Sep 10;16(3):304-313. doi: 10.1016/j.chom.2014.08.006.

Video Presentations

Broadly neutralizing HIV-1 antibody identified in a lupus patient
March 11, 2014
Dr. Barton Haynes, DHVI and Duke CHAVI-ID Director, discusses recent findings from a study led by DHVI investigators in which a broadly neutralizing antibody was identified in a lupus patient who was chronically infected with HIV.